Atossa Genetics (NASDAQ:ATOS) Issues Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Atossa Genetics (NASDAQ:ATOS) posted its quarterly earnings data on Friday. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.12), FiscalAI reports.

Atossa Genetics Trading Down 1.2%

NASDAQ:ATOS traded down $0.07 on Friday, hitting $5.60. 31,395 shares of the company’s stock were exchanged, compared to its average volume of 61,457. The firm has a 50-day moving average price of $5.18 and a 200-day moving average price of $8.28. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35.

Analyst Upgrades and Downgrades

ATOS has been the topic of several research reports. HC Wainwright boosted their price objective on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Ascendiant Capital Markets cut their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.33.

Institutional Investors Weigh In On Atossa Genetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP acquired a new position in shares of Atossa Genetics during the 2nd quarter worth about $26,000. JPMorgan Chase & Co. increased its stake in shares of Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares during the last quarter. &PARTNERS acquired a new position in shares of Atossa Genetics during the 4th quarter worth about $25,000. Bank of America Corp DE increased its stake in shares of Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares during the last quarter. Finally, XTX Topco Ltd increased its stake in shares of Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after purchasing an additional 144,412 shares during the last quarter. 12.74% of the stock is owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.